United States regulators have opened the door to a novel kind of Alzheimer’s trial: one that treats the disease not with a drug, but with a device designed to help the brain clear away toxic waste. The Food and Drug Administration has granted CereVasc an investigational device exemption for its eShunt System, allowing clinical testing in Alzheimer’s patients to begin.
How the eShunt Approach Works
The eShunt System diverts cerebrospinal fluid into the venous system through a minimally invasive, catheter-based procedure. The hypothesis behind the trial is that increasing the cycling of cerebrospinal fluid could support the brain’s natural ability to remove neurotoxins associated with Alzheimer’s disease. The need is vast: an estimated 7.4 million Americans aged 65 and older are currently living with Alzheimer’s, a figure projected to reach 13.8 million by 2060.
Experience From an Earlier Trial
CereVasc, based in Massachusetts, is not starting from zero. The company previously completed enrollment in its STRIDE clinical trial, which tested the same technology in normal pressure hydrocephalus, a different condition involving cerebrospinal fluid. That experience gives the team an existing safety and procedural track record as it moves into the far larger Alzheimer’s field. Readers can find more coverage like this under the latest health and medical device news.
What Happens Next for the Alzheimer’s Trial
As the full report on the FDA clearance notes, an investigational device exemption is a starting gun, not a finish line: it authorises trials, but the device must still demonstrate safety and benefit in patients before any wider use. There is no change to existing care for Alzheimer’s patients today, and expectations should stay measured — many promising approaches falter in trials.
Still, in a field dominated by pharmaceuticals, a mechanical approach to brain waste clearance is a genuinely different bet. The trial results, when they come, will be watched far beyond the neurology world.
